|
Status |
Public on Feb 09, 2021 |
Title |
HG2_CM272_R2 |
Sample type |
RNA |
|
|
Source name |
HepG2, hepatocellular carcinoma cell line, ATCC® HB-8065™, treated with CM272
|
Organism |
Homo sapiens |
Characteristics |
cell line: HepG2 treatment: CM272 at 400nM during 48 hours
|
Treatment protocol |
Cells were seeded at a density of 200000 cells / well in 6-well plates. After overnight incubation, cells were treated for 48 h with vehicle alone (0.1% DMSO) or with CM272 at 400nM in culture medium supplemented with 10% FBS (HepG2) or 2% FBS (LX2) and 100 U/ml penicillin-streptomycin in both cases.
|
Growth protocol |
Treatment with CM272 inhibitor at 400nM during 48hours. Control cells were treated with the correspondig vehicle alone (0.1% DMSO) during 48 hours.
|
Extracted molecule |
total RNA |
Extraction protocol |
Total RNA from cell lines was extracted using the automated Maxwell system from Promega (Madison, WI, USA) according to the manufacturer's instructions.
|
Label |
biotin
|
Label protocol |
The sense cDNA was prepared from 300 ng of total RNA using the Ambion® WT Expression Kit. The sense strand cDNA was then fragmented and biotinylated with the Affymetrix GeneChip® WT Terminal Labeling Kit (PN 900671).
|
|
|
Hybridization protocol |
Labeled sense cDNA was hybridized to the Affymetrix HuGene-2_0-st chip according to the the manufacturer protocols and using GeneChip® Hybridization, Wash and Stain Kit.
|
Scan protocol |
Genechips were scanned with the Affymetrix GeneChip® Scanner 3000.
|
Description |
HepG2 treated with CM272 400nM during 48h
|
Data processing |
The data were normalized, independently for each cell line, with Bioconductor software using RMA algorithm.
|
|
|
Submission date |
Feb 09, 2018 |
Last update date |
Feb 09, 2021 |
Contact name |
Maite G Fernandez-Barrena |
E-mail(s) |
magarfer@unav.es
|
Organization name |
CIMA
|
Street address |
Pio XII 55
|
City |
Pamplona |
ZIP/Postal code |
31008 |
Country |
Spain |
|
|
Platform ID |
GPL16686 |
Series (1) |
GSE110418 |
Expression data from HepG2 and LX2 cells treated with a dual epigenetic inhibitor of G9A and DNMT1. |
|